NextCure NXTC 深 滬
等待開盤 02-07 09:30:00 美东时间
11.10
+0.010
+0.09%
華盛通- 最 高11.40
- 今 開11.30
- 成交量 4384股
- 最 低 11.10
- 昨 收 11.09
- 總市值 3891.24万
- 52周最高 15.7399
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 2.688
- 委 比 20.95%
- 總股本 350.56万
- 歷史最高 1308.00
- 量 比 0.11
- 振 幅 2.71%
- 歷史最低 2.688
- 每 手 1
- 風險率 2.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NextCure Shares Update on Cancer Drug Trials, Cash Runway Extends Into 2027
NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a
01-23 20:05
BRIEF-Nextcure Provides Business Update
BRIEF-Nextcure Provides Business Update Jan 23 (Reuters) - NextCure Inc NXTC.O : NEXTCURE PROVIDES BUSINESS UPDATE NEXTCURE INC - SIM0505 PHASE 1 DATA UPDATE EXPECTED IN Q2 2026 NEXTCURE INC - EXPECTS FUNDS TO LAST INTO FIRST HALF OF 2027 Source text: ID:nGNX1GZ2wN Further company coverage: NXTC.O (
01-23 20:03
NextCure Provides Business Update
<p>NextCure, Inc. provided updates on its two antibody drug conjugate (ADC) programs. SIM0505 (CDH6 ADC) Phase 1 dose escalation data is expected in Q2 2026, with a focus on platinum-resistant ovarian cancer. The company is expanding clinical sites and drug supply for dose optimization. LNCB74 (B7-H4 ADC) has initiated higher dose cohorts in its Phase 1 study, prioritizing patients with high B7-H4 expression in breast and gynecological cancers, i...
01-23 12:00
NextCure Launches At-The-Market Stock Offering Program
NextCure ( ($NXTC) ) has shared an announcement. On December 19, 2025, NextCure...
2025-12-20 06:55
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
NextCure, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. A live audio webcast will be available through the company’s website, with a replay archived for 30 days. NextCure focuses on developing innovative cancer therapies, including antibody-drug conjugates, targeting patients who do not respond to current treatments. The company emphasizes understanding biological pathways and...
2025-11-20 13:00
NextCure Raises $21.5M in Private Placement
NextCure ( ($NXTC) ) has issued an announcement. On November 12, 2025, NextCure...
2025-11-17 21:44
NextCure shares are trading higher after the company announced a $21.5 million private placement.
NextCure shares are trading higher after the company announced a $21.5 million ...
2025-11-12 21:05
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target
Ladenburg Thalmann analyst Kevin DeGeeter upgrades NextCure (NASDAQ:NXTC) from Neutral to Buy and announces $18 price target.
2025-11-07 20:49
